X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

Content Team by Content Team
17th January 2022
in News
Ensovibep Therepeutic Candidate To Fight COVID-19 Makes Way

The phase 2 EMPATHY top-line data which is a DARP in therapeutic antiviral used in the COVID-19 treatment suggests that measurable and meaningful benefits were seen from Ensovibep over the placebo. The trial is being conducted by Novartis and has Molecular partners as its sponsor. The EMPATHY as it is called is randomized, placebo-controlled, double blind study, that is useful in cases of non-hospitalised adult patients that are suffering from COVID-19. 

The trial in its part A had 407 patients to identify Ensovibep dose with utmost safety and efficacy and had patients from India, South Africa, the Netherlands, Hungary, as well as the US. The participants were given three doses each of 75, 225, and 600mg. The primary finding of the trial suggested the viral load reduction over 8 days. The key secondary endpoints which were a part of the study revolved around emergency room visits or hospitalization to clinical recovery. As per the new data, Ensovibep could meet the primary endpoint with a significant reduction when it came to the viral load. 

The data in addition showed that the drug had a significant benefit over the placebo at two secondary endpoints having a decline of 78% in hospitalization or emergency room visits vis-a-vis the placebo.

The group with a placebo had 99 patients with round about 5 patients which needed hospitalization. Of the five two passed away due to COVID complications and one had an emergency room visit. On the other hand, of around 300 patients who got treated with Ensovibep, only two were hospitalised, while two had an ER visit and there were no deaths reported. The doses which were administered were tolerated by patients, thereby not giving any occurrence to safety -elated issues. Apparently, the lowest dose which is 75mg has been planned for further development and the new data will help to further determine the next step of action in the program. With these results, Novartis has said that it will go ahead with the option to seek license of Ensovibep from the sponsors and will also look out for expedited access across the world through USFDA and its emergency use authorization process. 

Vas Narasimhan who is the CEO at Novartis opines that the trial is positive and demonstrates a valuable effect of Ensovibep becoming a potential to treat COVID-19. Once the decision is made to go all out, the company will be responsible for manufacturing, the dose’s development, distribution, etc. Scaled-up activities have already been initiated by Novartis in its production facilities. To inactivate the COVID-19 Virus, Ensovibep is a therapeutic candidate. The DARPins in it have mono or therapies which are multi specific protein based needed to engage with the targets.

Previous Post

As Per WHO Omicron To Affect Above 50% of Europe In 2 Months

Next Post

Half-Million COVID Antibody Doses Sold By AstraZeneca To US

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
Next Post
Half-Million COVID Antibody Doses Sold By AstraZeneca To US

Half-Million COVID Antibody Doses Sold By AstraZeneca To US

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In